Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.55 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.55 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11922714 | 0.98 | SAT1 (0.57) | SAT1GNAI3GNAO1GNAI1CYP1A2 | |
| SCHEMBL27382583 | 0.94 | GNAI3 (0.62) | SAT1GNAI3GNAO1GNAI1CYP1A2 | |
| SCHEMBL8515191 | 0.94 | GNAI3 (0.62) | SAT1GNAI3GNAO1GNAI1CYP1A2 | |
| SCHEMBL24062846 | 0.93 | SAT1 (0.57) | SAT1GNAI3GNAO1GNAI1CYP1A2 | |
| SCHEMBL28709614 | 0.92 | GNAI3 (0.66) | SAT1GNAI3GNAO1GNAI1CYP1A2 | |
| SCHEMBL11576183 | 0.92 | GNAI3 (0.66) | SAT1GNAI3GNAO1GNAI1CYP1A2 | |
| SCHEMBL8603624 | 0.92 | GNAI3 (0.66) | SAT1GNAI3GNAO1GNAI1CYP1A2 | |
| SCHEMBL28997937 | 0.92 | GNAI3 (0.66) | SAT1GNAI3GNAO1GNAI1CYP1A2 | |
| SCHEMBL11922711 | 0.91 | GNAI3 (0.65) | SAT1GNAI3GNAO1GNAI1CYP1A2 | |
| Acetic Acid SCHEMBL5891651 | 0.91 | KDM4E (0.49) | SAT1GNAI3GNAO1GNAI1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| CN-109563085-A | piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-2308510-B1 | Agent for regeneration and/or protection of nerves | ONO PHARMACEUTICAL CO (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-8673889-B2 | BLT2-mediated disease, BLT2 binding agent and the compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8604207-B2 | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-8501793-B2 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20130143934-A1 | AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130085275-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070129327-A1 | Blood flow promoters for cauda equina tissues | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1790637-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1745800-A1 | NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-24 | — | — | EP | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20060194797-A1 | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-20060178399-A1 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1661892-A1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1623721-A1 | EFFECTOR CELL FUNCTION INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-02-08 | — | — | EP | disclosed |
| EP-1604981-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129327-A1 | Blood flow promoters for cauda equina tissues | PTGFR, PTGIS, PTGIR | SAT1 2539/4885GNAI3 754/4885GNAO1 763/4885 |
| US-10577363-B2 | Substituted piperidine compounds | SMYD3, SMYD2, SNRPD3 | SAT1 597/4885GNAI3 405/4885GNAO1 2302/4885 |
| US-20060178399-A1 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | HLA-DRB1, ELANE, MMP8 | SAT1 2431/4885GNAI3 300/4885GNAO1 750/4885 |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | SAT1 1989/4885GNAI3 1616/4885GNAO1 1398/4885 |
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | SAT1 597/4885GNAI3 405/4885GNAO1 2302/4885 |
| US-20130143934-A1 | AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES | PTGER3, PTGER2, PTGER1 | SAT1 4532/4885GNAI3 476/4885GNAO1 939/4885 |
| US-20060194797-A1 | Condensed ring compound and use thereof | CYSLTR2, CYSLTR1, LTB4R2 | SAT1 859/4885GNAI3 1745/4885GNAO1 2372/4885 |
| US-20130085275-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE AND MEDICINE CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CXCR3, CCR5, CCR1 | SAT1 3728/4885GNAI3 222/4885GNAO1 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.